<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500912</url>
  </required_header>
  <id_info>
    <org_study_id>NL73419.100.20</org_study_id>
    <nct_id>NCT04500912</nct_id>
  </id_info>
  <brief_title>Comparison of the Supraflex Cruz 60 Micron Versus the Ultimaster Tansei 80 Micron in HBR PCI Population</brief_title>
  <official_title>Comparison of the Supraflex Cruz 60 Micron Stent Strut Versus the Ultimaster Tansei 80 Micron Stent Strut in High Bleeding Risk PCI Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pieter C.Smits</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahajanand Medical Technologies Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Maatschap Cardiologen Rotterdam Zuid</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study compares the outcome of the ultrathin stent strut Supraflex Cruz stent to the thin&#xD;
      stent strut Ultimaster Tansei stent in a PCI population at high risk for bleeding (HBR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: An Investigator-initiated, multi-center, randomized clinical trial in HBR&#xD;
      patients receiving PCI with Supraflex Cruz or Ultimaster Tansei stents&#xD;
&#xD;
      Study population: 2 x 368 (736) patients, who undergo a PCI and are at high risk for bleeding&#xD;
      (HBR).&#xD;
&#xD;
      Intervention: Patients are treated according to the randomized regimen at index PCI and at&#xD;
      planned staged procedures. Either with the ultrathin stent strut Supraflex Cruz stent to the&#xD;
      thin stent strut Ultimaster Tansei stent&#xD;
&#xD;
      DAPT treatment (combination and duration) is according to the Guidelines of the European&#xD;
      Society of Cardiology for Myocardial Revascularization.&#xD;
&#xD;
      Follow-up is scheduled at 1 month, 6 months and 12 months post index PCI procedure.&#xD;
&#xD;
      Primary study parameters/outcome of the study:&#xD;
&#xD;
      The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of&#xD;
      cardiovascular death, myocardial infarction, target vessel revascularization, stroke and&#xD;
      bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Patient will be blinded for the stent that is used</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Net Adverse Clinical Endpoints (NACE)</measure>
    <time_frame>1 year</time_frame>
    <description>The primary endpoint Net Adverse Clinical Endpoints (NACE) defined as a composite of cardiovascular death, myocardial infarction, target vessel revascularization, stroke and bleeding events defined as BARC 3 or 5 at 12 months follow-up after the index PCI.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac and cerebral events (MACCE)</measure>
    <time_frame>1 year</time_frame>
    <description>Major adverse cardiac and cerebral events (MACCE) defined as a composite of cardiac death, myocardial infarction, target vessel revascularization and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major or clinically relevant non-major bleeding (MCB)</measure>
    <time_frame>1 year</time_frame>
    <description>Major or clinically relevant non-major bleeding (MCB) defined as a composite of type 2, 3 and 5 BARC bleeding events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Lesion Failure (TLF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target lesion revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel failure (TVF)</measure>
    <time_frame>1 year</time_frame>
    <description>Target Vessel Failure (TVF) is defined as cardiac death, myocardial infarction attributed to the target vessel and clinically indicated target vessel revascularization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of cardiovascular death, myocardial infarction and stroke</measure>
    <time_frame>1 year</time_frame>
    <description>The composite endpoint of cardiovascular death, myocardial infarction and stroke</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of cardiovascular death, myocardial infarction, stroke and major bleed BARC 3 and 5</measure>
    <time_frame>1 year</time_frame>
    <description>The composite of cardiovascular death, myocardial infarction, stroke and major bleed according to BARC 3 and 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>1 year</time_frame>
    <description>Stent thrombosis according to the ARC definitions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>1 year</time_frame>
    <description>Myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urgent target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Urgent target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Non-target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically indicated target vessel revascularization</measure>
    <time_frame>1 year</time_frame>
    <description>Clinically indicated target vessel revascularization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding events</measure>
    <time_frame>1 year</time_frame>
    <description>Bleeding events according to the BARC, TIMI and GUSTO classification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transfusion rates</measure>
    <time_frame>1 year</time_frame>
    <description>Transfusion rates both in patients with and/or without clinically detected over bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event rates according to the PRECISE-DAPT</measure>
    <time_frame>1 year</time_frame>
    <description>Event rates according to the PRECISE-DAPT score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>At completion of the baseline PCI</time_frame>
    <description>Procedural success is defined as angiographic success with no in-hospital MACE, defined as death, MI with new Q-waves on electrocardiogram (ECG) or urgent target vessel revascularization (TVR) (including both repeat PCI and coronary artery bypass graft surgery (CABG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>At discharge of baseline hospitalisation, on average 3 days</time_frame>
    <description>Device success (applying a lesion-level analysis)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">736</enrollment>
  <condition>Cardiac Disease</condition>
  <condition>PCI</condition>
  <condition>High Bleeding Risk</condition>
  <arm_group>
    <arm_group_label>Supraflex Cruz stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomization to Supraflex Cruz stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ultimaster Tansei stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomization to Ultimaster Tansei stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Supraflex Cruz 60 Micron</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>Supraflex Cruz stent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ultimaster Tansei 80 Micron</intervention_name>
    <description>percutaneous coronary intervention</description>
    <arm_group_label>Ultimaster Tansei stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Patients are eligible for inclusion into the study if the following criteria are met.&#xD;
&#xD;
          -  Patients of 18 years and above&#xD;
&#xD;
          -  Written or witnessed oral consent to participate in the study&#xD;
&#xD;
          -  Native coronary artery lesions eligible for PCI with stents with no restrictions in&#xD;
             number of lesions and stents, vessel size or lesion complexity, apart from stent&#xD;
             thrombosis.&#xD;
&#xD;
          -  Patients at high risk for bleeding according to the HBR ARC criteria: Patients meet&#xD;
             the HBR ARC criteria if ≥1 major or ≥2 minor criteria are met.&#xD;
&#xD;
        Major HBR criteria are the following:&#xD;
&#xD;
          -  Clinical indication for treatment with oral anticoagulants (OAC/NOAC) for at least 12&#xD;
             months&#xD;
&#xD;
          -  Severe or end-stage chronic kidney failure (GFR ≤ 30 ml/min)&#xD;
&#xD;
          -  Hemoglobin (Hb) level at screening &lt; 11g/dl or &lt; 6.8 mmol/l&#xD;
&#xD;
          -  Spontaneous bleeding requiring hospitalization or transfusion in the past 6 months or&#xD;
             at any time, if recurrent&#xD;
&#xD;
          -  Moderate or severe baseline true thrombocytopenia (platelet count &lt;100 *10^9/L)&#xD;
&#xD;
          -  History of chronic bleeding diathesis, like: leukemia, haemophilia, vitamin K&#xD;
             deficiency, Factor V or VII deficiency etc.&#xD;
&#xD;
          -  Liver cirrhosis with portal hypertension&#xD;
&#xD;
          -  Active malignancy (other than skin) within the past 12 months&#xD;
&#xD;
          -  Spontaneous intracranial haemorrhage ICH (at any time)&#xD;
&#xD;
          -  Traumatic intracranial haemorrhage ICH within 12 months&#xD;
&#xD;
          -  Presence of a brain arterio-venous malformation (AVM)&#xD;
&#xD;
          -  Moderate or severe ischemic stroke within the past 6 months&#xD;
&#xD;
          -  Nondeferrable major surgery on DAPT after PCI&#xD;
&#xD;
          -  Recent major surgery or major trauma within 30 d before PCI&#xD;
&#xD;
        Minor HBR criteria are the following:&#xD;
&#xD;
          -  Age ≥ 75 years&#xD;
&#xD;
          -  Moderate chronic kidney disease (GFR &gt;30 and &lt;60 ml/min)&#xD;
&#xD;
          -  Hemoglobin (Hb) 11-12.9 g/dL / 6.8-8.0 mmol/l for men and 11-11.9 g/dL / 6.8-7.4&#xD;
             mmol/l for women&#xD;
&#xD;
          -  Any ischemic stroke at any time not meeting the major criterion&#xD;
&#xD;
          -  Spontaneous bleeding requiring hospitalization or transfusion within the past 12&#xD;
             months&#xD;
&#xD;
          -  Need for chronic treatment with steroids or non-steroidal anti-inflammatory drugs&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients are not eligible if any of the following applies:&#xD;
&#xD;
          -  Treated with stents other than Supraflex Cruz or Ultimaster within 6 months prior to&#xD;
             index procedure&#xD;
&#xD;
          -  Treatment of lesions with stent thrombosis&#xD;
&#xD;
          -  Treatment of venous or arterial coronary grafts&#xD;
&#xD;
          -  Treated for stent thrombosis in 12 months prior to index PCI procedure&#xD;
&#xD;
          -  Treated with a bioresorbable scaffold 3 years before index PCI procedure&#xD;
&#xD;
          -  Cardiogenic shock at index procedure&#xD;
&#xD;
          -  Active SARS-CoV-2 infection or suspicion of SARS-CoV-2 infection&#xD;
&#xD;
          -  Cannot provide written informed consent&#xD;
&#xD;
          -  Under judicial protection, tutorship or curatorship&#xD;
&#xD;
          -  Unable to understand and follow study-related instructions or unable to comply with&#xD;
             study protocol&#xD;
&#xD;
          -  Active bleeding requiring medical attention (BARC≥2) at index PCI&#xD;
&#xD;
          -  Life expectancy less than one year&#xD;
&#xD;
          -  Known hypersensitivity or allergy for aspirin, clopidogrel, ticagrelor, prasugrel,&#xD;
             cobalt chromium or sirolimus&#xD;
&#xD;
          -  Any anticipated PCI after index PCI, unless planned and scheduled at index PCI&#xD;
&#xD;
          -  Participation in another stent or drug trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter Smits, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Maatschap Cardiologen Rotterdam Zuid</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter C Smits, MD, PhD</last_name>
    <phone>+31102913322</phone>
    <email>SmitsP@maasstadziekenhuis.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ria van Vliet</last_name>
    <phone>+31644162844</phone>
    <email>VlietM@maasstadziekenhuis.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jeroen Bosch ziekenhuis</name>
      <address>
        <city>'s-Hertogenbosch</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jawed Polad, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meander ziekenhuis</name>
      <address>
        <city>Amersfoort</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Fabrizio Spano, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rijnstate ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Danse, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tergooi ziekenhuis Blaricum</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Maribel Madera Camba, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Albert Schweitzer ziekenhuis</name>
      <address>
        <city>Dordrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rohit Oemrawsingh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catherina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pim Tonino, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MCL Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sjoerd Hofma, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St.Antonius ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>J-P van Kuijk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maasstadziekenhuis</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Valeria Paradies, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Zorgsaam</name>
      <address>
        <city>Terneuzen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Amar Al-Mafragi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>July 26, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Research Maatschap Cardiologen Rotterdam Zuid</investigator_affiliation>
    <investigator_full_name>Pieter C.Smits</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

